Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On Monday, Humana Inc. ( HUM - Analyst Report ) reduced its earnings per share (EPS) guidance for 2012 to $7.38–$7.58 from its earlier forecast of $7.55–$7.75. The downward revision resulted from a $45 million litigation expense incurred by the company’s military division – Humana Military Healthcare Services Inc.
Humana will incur the settlement charge in the second quarter of 2012. Consequently, the company also revised its second-quarter EPS guidance to $1.98–$2.08 from the previous guidance of $2.15–$2.25.
In 2008, Sacred Heart Health System Inc. and some other operators filed a lawsuit against Humana Military in a U.S. District Court in Florida, accusing the company of providing lower reimbursement rates than the contracted amount to some healthcare providers, thereby breaching its network agreements.
While the downward revision of EPS guidance by 17 cents per share looks to weigh on the investors’ sentiment, Humana’s financial position will not be seriously damaged as the company has adequate cash to pay the settlement charge. Humana had cash and cash equivalents of $3.66 billion, as of March 31, 2012.
The Zacks Consensus Estimate for Humana’s second-quarter 2012 earnings is currently $2.28 per share, down 8.8% from the year-ago quarter. For full-year 2012, the Zacks Consensus Estimate stands at $7.85 per share, up 0.4% from 2011.
Humana Inc. is one of the largest health care plan providers in the U.S. and competes with other industry heavyweights like WellPoint Inc. ( WLP - Analyst Report ) and Aetna Inc. ( AET - Analyst Report ) . Currently, the company carries a Zacks #3 Rank (short-term Hold rating). We also maintain a long-term ‘Neutral’ recommendation on the stock.
Read the full reports :
Analyst Report on WLP
Analyst Report on AET
Analyst Report on HUM